2021 Revenues ($USD) : $9,512,855,062
2021 Revenues (foreign currencies) : JP¥1,044,892,000,000
2021 R&D spend : $2,313,583,394
2021 Number of Employees : 16033
Fiscal Year End : 3/31/2022
Leader : CEO Sunao Manabe

Tokyo-based Daiichi Sankyo specializes in developing oncology and cardiovascular drugs, as well as vaccines. It has 17 R&D locations in 10 countries throughout the world. Key drugs from Daiichi Sankyo include Enhertu, a HER2-directed antibody and topoisomerase inhibitor conjugate developed in collaboration with AstraZeneca and launched in the U.S. in 2020. Other notable drugs include Olmersaran (benicar), Turalio (pexidartinib), Vanflyta (quizartinib), Lixiana/Savaysa (edoxaban), Emgality (galcanezumab-gnlm), Canalia (teneligliptin, canagliflozin) and Sevaysa (edoxaban). Daiichi Sankyo also has generics and OTC businesses. —BB